Scholar Rock Holding annual total liabilities
2017
2018
2019
2020
2021
2022
2023
2024
2025
Scholar Rock Holding Total Liabilities Growth & History (SRRK)
Scholar Rock Holding's total liabilities was $158.8M for fiscal 2025.
View full Scholar Rock Holding company overviewScholar Rock Holding annual total liabilities history
| Fiscal year | Period ended | Total liabilities | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $158.8M | $52.5M | +49.39% |
| 2024 | 2024-12-31 | $106.3M | $20.5M | +23.85% |
| 2023 | 2023-12-31 | $85.8M | −$12.1M | −12.37% |
| 2022 | 2022-12-31 | $97.9M | −$34.4M | −26.02% |
| 2021 | 2021-12-31 | $132.4M | $4.8M | +3.79% |
| 2020 | 2020-12-31 | $127.5M | $44.1M | +52.77% |
| 2019 | 2019-12-31 | $83.5M | $8.8M | +11.73% |
| 2018 | 2018-12-31 | $74.7M | $68.8M | +1160.55% |
| 2017 | 2017-12-31 | $5.9M | — | — |
Scholar Rock Holding quarterly total liabilities
Q4.17
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Total liabilities | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $269.8M | $163.0M | +152.70% |
| Q1 2026 | 2026-03-31 | $259.2M | $164.0M | +172.25% |
| Q4 2025 | 2025-12-31 | $158.8M | $52.5M | +49.39% |
| Q3 2025 | 2025-09-30 | $166.7M | $66.8M | +66.83% |
| Q2 2025 | 2025-06-30 | $106.8M | $13.5M | +14.49% |
| Q1 2025 | 2025-03-31 | $95.2M | $10.7M | +12.67% |
| Q4 2024 | 2024-12-31 | $106.3M | $20.5M | +23.85% |
| Q3 2024 | 2024-09-30 | $99.9M | $16.9M | +20.37% |
| Q2 2024 | 2024-06-30 | $93.2M | $10.8M | +13.16% |
| Q1 2024 | 2024-03-31 | $84.5M | −$1.6M | −1.81% |
| Q4 2023 | 2023-12-31 | $85.8M | −$12.1M | −12.37% |
| Q3 2023 | 2023-09-30 | $83.0M | −$14.0M | −14.44% |
| Q2 2023 | 2023-06-30 | $82.4M | −$12.2M | −12.92% |
| Q1 2023 | 2023-03-31 | $86.1M | −$8.6M | −9.08% |
| Q4 2022 | 2022-12-31 | $97.9M | −$34.4M | −26.02% |
| Q3 2022 | 2022-09-30 | $97.0M | −$14.1M | −12.68% |
| Q2 2022 | 2022-06-30 | $94.6M | −$20.8M | −18.00% |
| Q1 2022 | 2022-03-31 | $94.7M | −$25.4M | −21.15% |
| Q4 2021 | 2021-12-31 | $132.4M | $4.8M | +3.79% |
| Q3 2021 | 2021-09-30 | $111.1M | $10.7M | +10.64% |
| Q2 2021 | 2021-06-30 | $115.4M | $41.2M | +55.55% |
| Q1 2021 | 2021-03-31 | $120.0M | $43.0M | +55.79% |
| Q4 2020 | 2020-12-31 | $127.5M | $44.1M | +52.77% |
| Q3 2020 | 2020-09-30 | $100.4M | $33.7M | +50.47% |
| Q2 2020 | 2020-06-30 | $74.2M | $6.2M | +9.17% |
| Q1 2020 | 2020-03-31 | $77.1M | $3.6M | +4.90% |
| Q4 2019 | 2019-12-31 | $83.5M | $8.8M | +11.73% |
| Q3 2019 | 2019-09-30 | $66.8M | $60.1M | +900.03% |
| Q2 2019 | 2019-06-30 | $68.0M | $60.6M | +822.56% |
| Q1 2019 | 2019-03-31 | $73.5M | — | — |
| Q4 2018 | 2018-12-31 | $74.7M | $68.8M | +1160.55% |
| Q3 2018 | 2018-09-30 | $6.7M | — | — |
| Q2 2018 | 2018-06-30 | $7.4M | — | — |
| Q4 2017 | 2017-12-31 | $5.9M | — | — |
Scholar Rock Holding total liabilities trends
Over the last five fiscal years, Scholar Rock Holding's total liabilities increased from $127.5M to $158.8M, a change of $31.2M. The latest reported quarter, Q2 2026, shows $269.8M.
About the metric
What total liabilities mean
Total liabilities are all obligations reported on a company’s balance sheet, including debt, accounts payable, accrued expenses, deferred revenue, lease liabilities, and other current and long-term obligations.
Calculation and source
SEC-reported and calculated total liabilities
TickerStat uses total liabilities reported in company SEC filings when available. Otherwise, it calculates total liabilities as aligned total assets minus total equity for the same balance-sheet date. Total liabilities should not be confused with interest-bearing debt. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Scholar Rock Holding source filings ↗Community posts
Scholar Rock wins FDA approval for muscle-targeted SMA treatment
Scholar Rock ($SRRK) received FDA approval for ISEMBYLD, its apitegromab treatment for spinal muscular atrophy, in patients aged two and older receiving SMN2-targeted therapy. The company plans to begin shipping the medicine within days. Th ...